After Hunter Syndrome Setback, New Regenxbio Director Invests Nearly $1 Million

Newly appointed Regenxbio director Greg Ciongoli bought 102,603 shares for about $950,000 days after an FDA hold on Hunter syndrome therapy RGX-121.